The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

PUVA Therapy

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of PUVA Therapy


High impact information on PUVA Therapy

  • In contrast, PUVA therapy had no visible effect on ICAM-1 expression by papillary endothelial cells, but resulted in a significant reduction of the hemopoietic resident and infiltrating mononuclear cells within the epidermis [6].
  • Tyrosinase was detected in all skin samples with the highest levels in skin type IV and the lowest levels in skin type I. Following psoralen ultraviolet A (PUVA) therapy for several weeks, significant increases in the amounts of tyrosinase were found in skin types III and IV [7].
  • Five subjects who had received a mean total dose of 3.49 J/cm2 of UVB within a 4-week period had a mean SPF of 8.01 and 5 subjects who had received a mean total dose of 20 J/cm2 of UVA with PUVA therapy within 2 weeks had a mean SPF of 2 [8].
  • Variant frequencies were elevated in psoriatic and vitiligo patients receiving PUVA therapy and in conventionally-treated psoriatic patients [9].
  • 6-Thioguanine resistant peripheral blood lymphocytes in humans following psoralen, long-wave ultraviolet light (PUVA) therapy [9].

Chemical compound and disease context of PUVA Therapy


Anatomical context of PUVA Therapy

  • In one patient, abnormally high PHA-induced suppressor cell activities were recorded prior to treatment; after PUVA therapy the values were back to normal [13].
  • These results suggest a role for T cells in the pathogenesis of vitiligo and imply that previous PUVA therapy may be reflected by an alteration in circulating DR +ve cells [14].

Associations of PUVA Therapy with chemical compounds

  • BACKGROUND: Encouraging results of previous uncontrolled trials suggest that calcipotriol may potentiate the efficacy of psoralen plus ultraviolet (UV) A (PUVA) therapy in patients with vitiligo [15].
  • Patients living far from a specialized centre might be treated initially with PUVA therapy then with mechlorethamine alone, at home [16].
  • We conclude that anti-CD4 mAb administration can induce a rapid and major improvement in psoriatic lesions, with immunohistochemical changes different from those induced by cyclosporin A or 8-methoxypsoralen plus long wave UV light (PUVA) therapy [17].
  • When lesions cleared to less than 1% UVA-exposed body involvement, the methotrexate was stopped and PUVA therapy alone was used as maintenance therapy [18].
  • The supposed pathogenesis of photosensitivity reactions is reviewed, and the mechanism of action of drugs known to be efficient in this type of reaction (antimalarials, beta-carotene, thalidomide, PUVA therapy) discussed [19].

Gene context of PUVA Therapy

  • PUVA therapy might exhibit its beneficial effect, at least in part, by inhibiting COX-2 expression transcriptionally and translationally, with subsequent inhibition of PGE2 production [20].
  • In patients after PUVA therapy we observed decreased production of TNF-alpha and a decreased number of CD4+CD25+ cells in the blood compared with the same group of patients before the treatment [21].
  • Taken together, these results suggest the importance of MMP2 in melanoblast migration and in the response to PUVA therapy [22].
  • To determine whether an improvement in skin lesions as a result of PUVA therapy may be correlated with changes in cytokine patterns, RT-PCR amplification was used to compare the levels of IL-2, IL-6, IL-8, IL-10, TNF-alpha and IFN-gamma cytokine mRNA expression in serial biopsies from three chronic plaque psoriatic patients [23].
  • Furthermore, a gradual decrease in epidermal staining for IL-6 was observed in specimens from lesional skin of 6 patients with psoriasis taken before and during PUVA therapy, while staining of non-lesional skin remained unchanged [24].

Analytical, diagnostic and therapeutic context of PUVA Therapy

  • We have performed a retrospective study of 59 patients with vitiligo who received PUVA therapy from 1972 to 1986 [25].
  • In general, the antiproliferative activity of the new thioangelicin, tested in different biological substrates, appeared to be higher than that of the angelicin, the natural parent compound, but lower than that of 8-MOP, the furocoumarin ordinarily used in PUVA therapy and photopheresis [26].
  • Solar UV-irradiance was compared with radiation from different phototherapy devices (UVB, SUP, and PUVA therapy equipment) [27].
  • A novel approach to the management of vitiligo is described using a combination of epidermal autografts transplanted into the depigmented areas and psoralen-ultraviolet-A (PUVA) therapy [28].


  1. High prevalence of a variety of epidermodysplasia verruciformis-associated human papillomaviruses in psoriatic skin of patients treated or not treated with PUVA. Weissenborn, S.J., Höpfl, R., Weber, F., Smola, H., Pfister, H.J., Fuchs, P.G. J. Invest. Dermatol. (1999) [Pubmed]
  2. Treatments for androgenetic alopecia and alopecia areata: current options and future prospects. Meidan, V.M., Touitou, E. Drugs (2001) [Pubmed]
  3. Malignant melanoma in situ in two patients treated with psoralens and ultraviolet A. Marx, J.L., Auerbach, R., Possick, P., Myrow, R., Gladstein, A.H., Kopf, A.W. J. Am. Acad. Dermatol. (1983) [Pubmed]
  4. Transient hyperpigmentation after calcipotriol ointment and PUVA therapy in psoriatic patients. Vázqvez-López, F., Pérez-Oliva, N. Acta Derm. Venereol. (1996) [Pubmed]
  5. Skin carcinomas and treatment with photochemotherapy (PUVA). Lindskov, R. Acta Derm. Venereol. (1983) [Pubmed]
  6. Cyclosporin A suppresses ICAM-1 expression by papillary endothelium in healing psoriatic plaques. Petzelbauer, P., Stingl, G., Wolff, K., Volc-Platzer, B. J. Invest. Dermatol. (1991) [Pubmed]
  7. Tyrosinase synthesis in different skin types and the effects of alpha-melanocyte-stimulating hormone and cyclic AMP. Burchill, S.A., Marks, J.M., Thody, A.J. J. Invest. Dermatol. (1990) [Pubmed]
  8. Natural and artificial photoprotection. Cripps, D.J. J. Invest. Dermatol. (1981) [Pubmed]
  9. 6-Thioguanine resistant peripheral blood lymphocytes in humans following psoralen, long-wave ultraviolet light (PUVA) therapy. Strauss, G.H., Albertini, R.J., Krusinski, P.A., Baughman, R.D. J. Invest. Dermatol. (1979) [Pubmed]
  10. Treatment of patients with psoriasis by PUVA therapy and mechlorethamine. Mauduit, G., Salle, G., Schott, A.M., Thivolet, J. Br. J. Dermatol. (1986) [Pubmed]
  11. Therapy of psoriasis with retinoid plus PUVA: clinical and histologic data. Heidbreder, G., Christophers, E. Arch. Dermatol. Res. (1979) [Pubmed]
  12. PUVA combination therapy. Morison, W.L. Photo-dermatology. (1985) [Pubmed]
  13. PUVA treatment in chromium hypersensitivity: effect on skin reactivity and lymphocyte functions. Jansén, C.T., Viander, M., Kalimo, K., Soppi, A.M., Soppi, E. Arch. Dermatol. Res. (1981) [Pubmed]
  14. Peripheral T-cell activation in non-segmental vitiligo. Mahmoud, F., Abul, H., al-Saleh, Q., Haines, D., Burleson, J., Morgan, G. J. Dermatol. (1998) [Pubmed]
  15. Is the efficacy of psoralen plus ultraviolet A therapy for vitiligo enhanced by concurrent topical calcipotriol? A placebo-controlled double-blind study. Ermis, O., Alpsoy, E., Cetin, L., Yilmaz, E. Br. J. Dermatol. (2001) [Pubmed]
  16. PUVA therapy prevents sensitization to mechlorethamine in patients with psoriasis. Mauduit, G., Silvestre, O., Thivolet, J. Br. J. Dermatol. (1985) [Pubmed]
  17. Anti-CD4 monoclonal antibody therapy in severe psoriasis. Morel, P., Revillard, J.P., Nicolas, J.F., Wijdenes, J., Rizova, H., Thivolet, J. J. Autoimmun. (1992) [Pubmed]
  18. Combined methotrexate-PUVA therapy in the treatment of psoriasis. Morison, W.L., Momtaz, K., Parrish, J.A., Fitzpatrick, T.B. J. Am. Acad. Dermatol. (1982) [Pubmed]
  19. The pharmacological basis for the treatment of photodermatoses. Peyron, J.L., Meynadier, J. Biochimie (1986) [Pubmed]
  20. Cyclooxygenase-2 expression and prostaglandin E2 biosynthesis are enhanced in scleroderma fibroblasts and inhibited by UVA irradiation. Kanekura, T., Higashi, Y., Kanzaki, T. J. Rheumatol. (2001) [Pubmed]
  21. Influence of systemic photochemotherapy on regulatory T cells and selected cytokine production in psoriatic patients: a pilot study. Rotsztejn, H., Zalewska, A., Trznadel-Budźko, E., Lewkowicz, P., Banasik, M., Tchórzewski, H., Głowacka, E. Med. Sci. Monit. (2005) [Pubmed]
  22. In vitro migration of melanoblasts requires matrix metalloproteinase-2: implications to vitiligo therapy by photochemotherapy. Lei, T.C., Vieira, W.D., Hearing, V.J. Pigment Cell Res. (2002) [Pubmed]
  23. Cytokine expression in psoriatic skin lesions during PUVA therapy. Olaniran, A.K., Baker, B.S., Paige, D.G., Garioch, J.J., Powles, A.V., Fry, L. Arch. Dermatol. Res. (1996) [Pubmed]
  24. Epidermal expression of interleukin-6 and tumour necrosis factor-alpha in normal and immunoinflammatory skin states in humans. Oxholm, A. APMIS Suppl. (1992) [Pubmed]
  25. PUVA treatment of vitiligo: a retrospective study of 59 patients. Wildfang, I.L., Jacobsen, F.K., Thestrup-Pedersen, K. Acta Derm. Venereol. (1992) [Pubmed]
  26. Synthesis of angelicin heteroanalogues: preliminary photobiological and pharmacological studies. Mosti, L., Lo Presti, E., Menozzi, G., Marzano, C., Baccichetti, F., Falcone, G., Filippelli, W., Piucci, B. Farmaco (1998) [Pubmed]
  27. Midsummer solar UV-radiation in Finland compared with the UV-radiation from phototherapeutic devices measured by different techniques. Kolari, P.J., Lauharanta, J., Hoikkala, M. Photo-dermatology. (1986) [Pubmed]
  28. Autografting and PUVA. A combination therapy for vitiligo. Skouge, J.W., Morison, W.L., Diwan, R.V., Rotter, S. The Journal of dermatologic surgery and oncology. (1992) [Pubmed]
WikiGenes - Universities